Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcatheter Tricuspid Valve Replacement Reduces Heart Failure Hospitalization: Insights From the Canadian Evoque Registry.

The Canadian journal of cardiology·2026
Same author

Tricuspid Transcatheter-Edge-to-Edge-Repair and Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation: Patient Profiles and Outcomes.

CJC open·2026
Same author

Impact of TAVR Failure Mechanism on Outcomes After Reintervention: From the EXPLANTORREDO-TAVR Registry.

Circulation. Cardiovascular interventions·2026
Same author

Automated Referral Prompts Reveal Lack of Equitable Access to Care in Patients With Aortic Stenosis.

Structural heart : the journal of the Heart Team·2026
Same author

Incidence, Clinical Implications, and Predictors of Paravalvular Leak Following Transcatheter Tricuspid Valve Replacement: The TRIPLACE Registry.

JACC. Cardiovascular interventions·2026
Same author

The influence of reoperation on aortic arch reconstructive surgery: Evidence from a multicenter, national registry.

The Journal of thoracic and cardiovascular surgery·2026

Related Experiment Video

Updated: May 28, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Microaxial devices for ventricular failure: a multicentre, population-based experience.

Jennifer Higgins1, Yoan Lamarche, Annemarie Kaan

  • 1Division of Cardiac Surgery, St Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.

The Canadian Journal of Cardiology
|October 11, 2011
PubMed
Summary
This summary is machine-generated.

Impella microaxial ventricular assist devices offer temporary circulatory support for acute decompensated heart failure. This study found Impella devices to be a valuable option in selected patients, despite a 40% 30-day mortality rate.

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Related Experiment Videos

Last Updated: May 28, 2026

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Area of Science:

  • Cardiology
  • Mechanical Circulatory Support
  • Heart Failure Management

Background:

  • Impella microaxial devices provide circulatory support for acute decompensated heart failure.
  • This study examines the provincial experience with Impella devices in British Columbia.

Purpose of the Study:

  • To review the population-based provincial experience with Impella microaxial devices.
  • To evaluate the use of Impella devices in patients with acute decompensated heart failure and cardiogenic shock.

Main Methods:

  • Retrospective review of a prospectively maintained database.
  • Impella devices were used for acute cardiogenic shock refractory to maximal therapy, as a bridge to decision or long-term mechanical support.

Main Results:

  • 35 patients received 37 Impella devices between August 2007 and September 2009.
  • Mean age was 53.0±13.7 years, with a mean ejection fraction of 19±9%. Most patients required aggressive resuscitation and were on inotropic support and mechanical ventilation.
  • 49% were successfully weaned, 22% transferred to long-term support, and 4 to cardiac transplantation. 30-day and 6-month mortality rates were 40% and 49%, respectively. Complications included bleeding and thrombocytopenia.

Conclusions:

  • Temporary support with Impella microaxial ventricular assist devices is a valuable therapeutic option.
  • Careful patient selection is crucial for optimal outcomes in acute decompensated heart failure.